Legend Biotech ($LEGN) was mentioned 17 times over the past 12 months by 4 distinct FinTwit voices, with the first mention appearing on September 10, 2025. Jacob Plieth (@jacobplieth) dominated the conversation with all 17 mentions, followed by Cobra (@cobraalerts) with 5 mentions, while Adam Feuerstein and Jon Erlichman each contributed 1 mention. The biotech category was the primary focus for $LEGN discussions.

The most recent activity centered on clinical trial data presented at EHA2026 in early June 2026. Jacob Plieth reported that the in vivo CD19 x CD20 CAR-T candidate LB2501 achieved 0% ORR at dose level 1 but showed 100% ORR (6/6) and 83% CR rate (5/6) at dose level 2. By mid-June, discussion expanded to include a fourth in vivo CAR-T program, LVIVO-TaVec122, with undisclosed targets, indicating ongoing pipeline expansion for the company.